The sixth Asia Summit on Global Health (ASGH) was held in Hong Kong under the theme Fuelling Healthcare Breakthroughs, bringing together leaders from government, industry, research, investment and the broader healthcare innovation ecosystem. More than 90 experts and industry representatives from 15 countries and regions took part in discussions on healthcare innovation, artificial intelligence, cross-border collaboration and the future of healthcare.
As one of the Asia-Pacific region’s influential platforms for healthcare dialogue and collaboration, ASGH focuses on healthcare innovation, industry collaboration and cross-border partnerships, providing a high-level forum for stakeholders across the healthcare value chain. At the invitation of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), Jack Wang, Chairman of WinHealth Pharma, joined a high-level delegation of Chinese pharmaceutical companies in Hong Kong to attend the summit and participate in related industry dialogues.
During the summit, WinHealth Pharma participated in two industry dialogues: the Chinese Mainland-Hong Kong Pharmaceutical Regulatory Policy and Industry Development Exchange, co-hosted by PhIRDA and the Hong Kong Bio-Med Innovation Association, and the Chinese Mainland-Hong Kong Exchange on the Internationalization of Pharmaceutical Innovation, co-hosted by PhIRDA and Hong Kong Science and Technology Parks Corporation. Discussions focused on the continued development of Hong Kong’s pharmaceutical and medical device regulatory framework, as well as pathways for innovative medicines to reach broader markets. Key topics included policy and regulatory coordination, alignment with international standards, real-world evidence, multi-regional clinical trials, ecosystem development and global talent development. Participants explored how to strengthen linkages across R&D, registration, clinical translation and commercialization, with the aim of supporting a more open and globally competitive biopharmaceutical innovation ecosystem.
Jack Wang, Chairman of WinHealth Pharma, said: “For healthcare innovation to reach international markets, progress in any single area is not enough. It requires the combined strength of R&D capabilities, clinical evidence, regulatory pathways, capital markets and commercialization capabilities. As an international financial center, Hong Kong has an open market environment, mature capital markets, a globally connected professional services network and an evolving pharmaceutical and medical device regulatory environment. We welcome the Hong Kong SAR Government’s continued efforts to advance the “1+” mechanism for approval of new drugs and to build a more systematic and standardized regulatory review and approval framework. We also hope to see more innovative medicines that address clear unmet medical needs benefit from Hong Kong’s open, professional and internationally aligned ecosystem to accelerate registration, approval and clinical use, while exploring broader access pathways across international markets. Guided by our Patients-First philosophy, WinHealth Pharma will continue to connect with global innovation networks and work with partners to translate meaningful innovation into tangible patient benefit.”
About WinHealth Pharma
WinHealth Pharma is a China-based integrated pharmaceutical company with a core focus on kidney diseases and strategic expansion into hematology and other major therapeutic areas. It possesses comprehensive capabilities across the entire pharmaceutical value chain from research and development to manufacturing and commercialization. Guided by its “Patients-First” philosophy and the mission of “Advancing Health, Empowering Lives,” the company is dedicated to improving patients' quality of life through innovative therapies. By leveraging a multi-strategy-driven business model, WinHealth Pharma connects with global innovations to continuously build a diverse, differentiated, and highly competitive product portfolio. Anchoring a strong presence in China, the company is actively expanding into other Asian markets and key international regions, including Switzerland and Japan. WinHealth Pharma is committed to fostering an open and collaborative healthcare ecosystem, driving industry innovation to meet the evolving needs of patients worldwide. For more information, please visit www.winhealth.hk.